Recursion Q2 2026: Narrower Loss, Extended Runway, and Genentech's First Neuroscience Target Option
RXRX is trading near its 52-week low of $2.77 (7.2% above the low).
Summary
Recursion's Q2 2026 results feature a narrowing loss, extended cash runway, and lowered expense guidance. Genentech's option of the first neuroscience target validates the AI platform, while REC-7735 IND clearance and upcoming REC-4881 data add near-term catalysts.
Updates
· Reuters — Q2 revenue was $7.3M, missing consensus by 39%, and net loss of $131M was wider than the $119M analysts expected.
· SEC 10-Q — Cash and cash equivalents were $545.7M at June 30, 2026, with total cash including restricted cash of $556.8M. The 10-Q discloses material weaknesses in internal control over financial reporting that persist.
Key Events · Earnings and Guidance · RXRX
-
Q2 2026 Financial Results
Net loss narrowed to $131.0M from $171.9M in Q2 2025. Revenue was $7.7M, down from $19.2M due to completion of certain Roche/Genentech project phases. Cash, cash equivalents and restricted cash totaled $556.8M as of June 30, 2026, with runway into early 2028.
-
Lowered Cash Operating Expense Guidance
2026 cash operating expense guidance reduced to <$375M from <$390M, reflecting ~40% reduction from pro forma 2024 levels, driven by operating efficiencies and lower platform costs.
-
Genentech Options First Neuroscience Target
Genentech exercised the first validated target option under the neuroscience collaboration, advancing a previously unexplored target into a joint early discovery program. This milestone provides early evidence that Recursion's AI platform can generate novel, biologically validated targets.
-
REC-7735 IND Cleared, Phase 1/2 Trial in 2H26
The IND for REC-7735, a >100x mutant-selective PI3Kα H1047R inhibitor designed to improve therapeutic index, was cleared. The Phase 1/2 ZINNIA trial in select solid tumors will initiate in the second half of 2026.
Analysis · RXRX · Life Sciences
A narrower net loss of $131.0M, down from $171.9M a year ago, was driven by lower R&D and G&A expenses. Cash, cash equivalents, and restricted cash reached $556.8M as of June 30, 2026, extending the runway into early 2028. Reflecting improved operating efficiency, 2026 cash operating expense guidance was lowered to <$375M from <$390M. In a critical validation of the AI-native platform, Genentech exercised the first validated target option under the neuroscience collaboration, advancing a previously unexplored target into early discovery. The IND for REC-7735, a mutant-selective PI3Kα inhibitor, was cleared, with a Phase 1/2 trial starting in 2H26. Additional Phase 2 data for REC-4881 in FAP will be presented at a major medical meeting in November 2026. These updates, combined with new executive hires in AI and drug design, reinforce the company's transition from a platform-centric to a product-focused engine with multiple near-term catalysts.
How filings like this one have moved
In the 30 days to Sep 30, 2026, 34.7% of the 1013 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.50%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, RXRX was trading at $2.97 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.8B. The 52-week trading range was $2.77 to $7.18. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.